UniProt Q96L34 · PDB · AlphaFold · Substrate: CHKtide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 97.9% | 2.1% | 78.64 | 0.500 |
| 2 | Brigatinib | 91.8% | 8.2% | 82.96 | 0.513 |
| 3 | Defactinib | 83.0% | 17.0% | 92.68 | 0.450 |
| 4 | Sunitinib | 72.3% | 27.7% | 91.73 | 0.524 |
| 5 | Repotrectinib | 70.9% | 29.1% | 84.21 | 0.608 |
| 6 | Axitinib | 65.6% | 34.4% | 93.23 | 0.688 |
| 7 | Baricitinib | 64.2% | 35.8% | 97.99 | 0.616 |
| 8 | Fedratinib | 56.9% | 43.1% | 96.21 | 0.576 |
| 9 | Bosutinib | 52.4% | 47.6% | 87.22 | 0.555 |
| 10 | Upadacitinib | 51.6% | 48.4% | 97.98 | 0.663 |
| 11 | Crizotinib | 45.3% | 54.7% | 91.39 | 0.581 |
| 12 | Pemigatinib | 42.9% | 57.1% | 98.23 | 0.718 |
| 13 | Nintedanib | 37.5% | 62.5% | 90.23 | 0.608 |
| 14 | Ruxolitinib | 33.6% | 66.4% | 98.25 | 0.592 |
| 15 | Abrocitinib | 32.8% | 67.2% | 99.50 | 0.581 |
| 16 | Selpercatinib | 30.0% | 70.0% | 96.72 | 0.635 |
| 17 | Neratinib | 26.9% | 73.1% | 93.18 | 0.597 |
| 18 | Rabusertib | 25.5% | 74.5% | 98.74 | 0.687 |
| 19 | Pacritinib | 24.9% | 75.1% | 88.64 | 0.452 |
| 20 | Capivasertib | 20.9% | 79.1% | 96.48 | 0.644 |
Paralog block
MARK1, MARK2_PAR_1BA, MARK3, MARK4
EMT expression
- Mesenchymal log2(TPM+1): 4.21
- Epithelial log2(TPM+1): 3.60
- Fold change: 0.62
- Status: No significant change
Selectivity landscape vs inhibition on MARK4
Each point is one of the 92 approved drugs; color = inhibition % on MARK4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…